Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Siolta Therapeutics.

    Client Virtual Booth

    SIOLTA THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Siolta Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    930 Brittan Ave. San Carlos, CA 94070
    Telephone
    Telephone
    415.991.0947
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sioltatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/siolta-therapeutics/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

    Details:

    The financing aims to support the advancement of the Siolta clinical program STMC-103H, which is being evaluated in Phase I/II clinical trial studies for the treatment of Atopic Dermatitis and Type 1 Hypersensitivity.


    Lead Product(s): STMC-103H

    Therapeutic Area: Dermatology Product Name: STMC-103H

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: SymBiosis and Khosla Ventures

    Deal Size: $12.0 million Upfront Cash: Undisclosed

    Deal Type: Series C Financing March 12, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for th...

    Details:

    STMC-103H is a Live Biotherapeutic Product (LBP) for the prevention and treatment of atopic diseases (atopic dermatitis, atopic asthma, food allergy, allergic rhinitis) in at-risk newborns based on an immediate family history of atopic diseases.


    Lead Product(s): STMC-103H

    Therapeutic Area: Dermatology Product Name: STMC-103H

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Siolta Therapeutics Awarded NIH Grant

    Details:

    The grant will provide funding for the continued development and optimization of manufacturing approaches for live biotherapeutic products containing strictly anaerobic, non-spore forming bacteria as active pharmaceutical ingredients including STMC-103H.


    Lead Product(s): STMC-103H

    Therapeutic Area: Dermatology Product Name: STMC-103H

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases

    Deal Size: $1.0 million Upfront Cash: Undisclosed

    Deal Type: Funding February 09, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

    Details:

    The latest round of capital will go towards supporting clinical proof of concept (POC) trials testing the efficacy of their lead LBP product, STMC-103H.


    Lead Product(s): STMC-103H

    Therapeutic Area: Immunology Product Name: STMC-103H

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Khosla Ventures

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing September 22, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search